Panagora Asset Management’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-114,014
| Closed | -$209K | – | 1452 |
|
|
2022
Q2 | $209K | Buy |
114,014
+9
| +0% | +$16 | ﹤0.01% | 1399 |
|
|
2022
Q1 | $304K | Buy |
114,005
+1,072
| +0.9% | +$2.86K | ﹤0.01% | 1354 |
|
|
2021
Q4 | $489K | Buy |
112,933
+117
| +0.1% | +$507 | ﹤0.01% | 1224 |
|
|
2021
Q3 | $574K | Buy |
112,816
+19,123
| +20% | +$97.3K | ﹤0.01% | 1250 |
|
|
2021
Q2 | $593K | Buy |
93,693
+71,000
| +313% | +$449K | ﹤0.01% | 1257 |
|
|
2021
Q1 | $175K | Sell |
22,693
-75,788
| -77% | -$584K | ﹤0.01% | 1753 |
|
|
2020
Q4 | $645K | Sell |
98,481
-173,252
| -64% | -$1.13M | ﹤0.01% | 1135 |
|
|
2020
Q3 | $1.81M | Sell |
271,733
-88,867
| -25% | -$591K | 0.01% | 693 |
|
|
2020
Q2 | $3M | Buy |
360,600
+8,016
| +2% | +$66.8K | 0.02% | 539 |
|
|
2020
Q1 | $2.7M | Sell |
352,584
-129,953
| -27% | -$997K | 0.02% | 508 |
|
|
2019
Q4 | $4.01M | Buy |
+482,537
| New | +$4.01M | 0.02% | 547 |
|
|
2019
Q2 | – | Sell |
-65,159
| Closed | -$700K | – | 2621 |
|
|
2019
Q1 | $700K | Sell |
65,159
-23,371
| -26% | -$251K | ﹤0.01% | 1274 |
|
|
2018
Q4 | $1.34M | Sell |
88,530
-91,709
| -51% | -$1.39M | 0.01% | 951 |
|
|
2018
Q3 | $3.33M | Sell |
180,239
-35,509
| -16% | -$657K | 0.01% | 654 |
|
|
2018
Q2 | $4.93M | Buy |
215,748
+56,734
| +36% | +$1.3M | 0.02% | 530 |
|
|
2018
Q1 | $4.52M | Sell |
159,014
-28,643
| -15% | -$815K | 0.02% | 572 |
|
|
2017
Q4 | $3.96M | Buy |
187,657
+61,767
| +49% | +$1.3M | 0.01% | 622 |
|
|
2017
Q3 | $2.29M | Hold |
125,890
| – | – | 0.01% | 812 |
|
|
2017
Q2 | $1.95M | Buy |
125,890
+125,834
| +224,704% | +$1.95M | 0.01% | 870 |
|
|
2017
Q1 | $1K | Buy |
+56
| New | +$1K | ﹤0.01% | 2343 |
|